Prof Gilles Salles speaks at an EHA 2010 press conference about the PRIMA study which has shown that retuximab 'maintenance' therapy after initial treatment of retuximab plus chemotherapy reduces the risk of follicular lymphoma recurrence by up to 50%. Prof Salles discusses the effects this treatment has on patients, how he expects these results to change clinical practice and his hopes for the development of further effective antibody treatments.